Key result
Elevated admission HFABP, NT-proBNP, and pulmonary artery pressures predict 6-month mortality in acute PE.
Why the study?
Right ventricular dysfunction with myocardial damage can cause fatal complications in acute pulmonary embolism, prompting evaluation of cardiac biomarkers and right ventricular dysfunction for short-term mortality.
Do cardiac biomarkers (HFABP, NT-proBNP) and pulmonary artery pressures measured on admission predict 6-month mortality and complicated clinical course in patients with acute pulmonary embolism?
Observational (n=41)
No
Do cardiac biomarkers (HFABP, NT-proBNP) and pulmonary artery pressures measured on admission predict 6-month mortality and complicated clinical course in patients with acute pulmonary embolism?
Hazard Ratio: 1.02 (95% CI 1.01–1.05)
May aid early risk stratification in acute PE; leaves open confirmation in larger prospective cohorts.
Objective: Right ventricular dysfunction (RVD) with myocardial damage may lead to fatal complications in patients with acute pulmonary embolism (PE). Cytoplasmic heart-type fatty acid-binding protein (HFABP) and the N-terminal fragment of its prohormone (NT-proBNP) are sensitive and specific biomarkers of myocardial damage. We evaluated RVD and cardiac biomarkers for myocardial damage and short-term mortality in patients with acute PE. Materials and Methods: We analyzed 41 patients (24 females, 17 males) with confirmed acute PE prospective. Three groups (massive, submassive, and nonmassive) of patients were defined, based on systemic systolic blood pressure measured on admission and RVD by transthoracic echocardiography (TTE). Also, systolic (s) and mean (m) pulmonary artery pressures (PAPs) were recorded by TTE, and plasma concentrations of cardiac troponin T (cTn-T), NT-proBNP, and HFABP were evaluated 6 month follow-up. Results: Seventeen (41.5%) patients experienced a complicated clinical course in the 6-month follow-up for the combined end-point, including at least one of the following: death (n=12, 29.3%; 3 PE-related), chronic PE (n=4, 9.8%), pulmonary hypertension (n=2, 4.9%), and recurrent PE (n=1, 2.4%). Multivariate hazard ratio analysis revealed HFABP, NT-proBNP, and PAPs as the 6-month mortality predictors (HR 1.02, 95% CI 1.01- 1.05; HR 1.01, 95% CI 1.01-1.04; and HR 1.02, 95% CI 1.02-1.05, respectively). Conclusion: HFABP, NT-proBNP, and PAPs measured on admission may be useful for short-term risk stratification and in the prediction of 6-month PE-related mortality in patients with acute PE. (Anatol J Cardiol 2016; 16: 276-82)
No takes yet. Share an insight, caveat, or question.
Neşe Dursunoğlu (2024) conducted an observational in Acute pulmonary embolism (n=41). Elevated HFABP, NT-proBNP, and pulmonary artery pressures vs. Lower biomarker levels/pressures was evaluated on 6-month mortality (predicted by HFABP) (HR 1.02, 95% CI 1.01-1.05). Elevated levels of HFABP, NT-proBNP, and pulmonary artery pressures measured on admission were significant predictors of 6-month mortality in patients with acute pulmonary embolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: